Literature DB >> 23557236

Evaluation of the mutagenicity and genotoxicity of Arrabidaea chica Verlot (Bignoneaceae), an Amazon plant with medicinal properties.

Vinícius Carlotto dos Santos1, Thais Basso Longo, Ana Letícia Hilário Garcia, Marc François Richter, Temenouga Nikolova Guecheva, João Antonio Pêgas Henriques, Alexandre de Barros Falcão Ferraz, Jaqueline Nascimento Picada.   

Abstract

Arrabidaea chica Verlot (Bignoniaceae) is an important folk medicine plant native to the Amazon region and used to treat anemia, hemorrhage, inflammation, intestinal colic, hepatitis, and skin affections. Although studies showed its therapeutic properties, little knowledge regarding genotoxic properties of this plant is available. The aim of this study was to determine the potential mutagenic and genotoxic/antigenotoxic effects of an A. chica chloroformic fraction (Ac-CF) obtained from leaves containing bioactive metabolites. The mutagenic effects were evaluated using the Salmonella mutagenicity assay, with TA98, TA97a, TA100, TA102, and TA1535 strains, with and without metabolic activation. In vivo mutagenic and genotoxic/antigenotoxic effects were investigated using the micronucleus (MN) test in bone marrow and alkaline comet assay in blood and liver after administration of 100, 500, or 1000 mg/kg Ac-CF in CF-1 mice by gavage (once a day for 3 d). In vitro antioxidant potential was evaluated using DPPH and xanthine/hypoxanthine assays. Ac-CF was not mutagenic in any of the Salmonella typhimurium strains tested and showed negative responses for mutagenicity and genotoxicity in mice. Further, Ac-CF displayed antigenotoxic effects by decreasing the oxidative DNA damage induced by hydrogen peroxide by greater than 50% in blood and liver. The antioxidant action detected in the in vitro assays demonstrated IC50 of 0.838 mg/ml in the xanthine/hypoxanthine assay and IC50 of 28.17 μg/ml in the DPPH assay. In conclusion, Ac-CF did not induce mutagenic and genotoxic effects and was able to protect DNA against oxidative damage in vivo, suggesting that this fraction may not pose genetic risks, although further toxicology assays are necessary.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23557236     DOI: 10.1080/15287394.2012.761947

Source DB:  PubMed          Journal:  J Toxicol Environ Health A        ISSN: 0098-4108


  4 in total

Review 1.  A Review of the Phytochemistry and Pharmacological Properties of the Genus Arrabidaea.

Authors:  Jessyane Rodrigues do Nascimento; Amanda de Jesus Alves Miranda; Felipe Costa Vieira; Carla Daniele Pinheiro Rodrigues; Luna Nascimento Vasconcelos; José Lima Pereira Filho; Auxiliadora Cristina Corrêa Barata Lopes; Marcelo Marucci Pereira Tangerina; Wagner Vilegas; Cláudia Quintino da Rocha
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-25

Review 2.  Therapeutic Potential of Leaves from Fridericia chica (Bonpl.) L. G. Lohmann: Botanical Aspects, Phytochemical and Biological, Anti-Inflammatory, Antioxidant and Healing Action.

Authors:  Adriane Dâmares de Sousa Jorge Batalha; Damy Caroline de Melo Souza; Rosmery Duran Ubiera; Francisco Celio Maia Chaves; Wuelton Marcelo Monteiro; Felipe Moura Araújo da Silva; Hector Henrique Ferreira Koolen; Antônio Luiz Boechat; Marco Aurélio Sartim
Journal:  Biomolecules       Date:  2022-08-31

3.  Arrabidaea chica for oral mucositis in patients with head and neck cancer: a protocol of a randomised clinical trial.

Authors:  Núbia de Cassia Almeida Queiroz; Michelle Pedroza Jorge; Ilza Maria de Oliveira Sousa; Carmen Silvia Passos Lima; Maria Christina de Miranda Matias; Ana Cristina Dal Rio; Eduardo Baldon Pereira; Victória Hahn Kakas Galassi; João Ernesto de Carvalho; Tais Freire Galvao; Mary Ann Foglio
Journal:  BMJ Open       Date:  2018-10-18       Impact factor: 2.692

4.  Arrabidaea chica chloroform extract modulates estrogen and androgen receptors on luminal breast cancer cells.

Authors:  Douglas C Brandão; Paula M A P Lima; Isabella C Martins; Carina S Cordeiro; Antonielle O Cordeiro; Lara Vecchi; Joyce F C Guerra; Priscila C Orsolin; Matheus C Gazolla; Danilo S Costa; Ademar A da Silva Filho; Thaise G Araújo
Journal:  BMC Complement Med Ther       Date:  2022-01-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.